Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Flonoltinib Maleate as a JAK/FLT3 dual target inhibitor, previous pharmacological experiments
showed that the IC50 inhibition of JAK2 kinase was as low as 0.8 nM, while the IC50
inhibition of JAK1, JAK3 and TYK2 kinases was 26 nM, 39 nM and 2 nM, respectively, and the
IC50 of FLT3 kinase was 15 nM. It has high inhibitory activity for JAK2 kinase and good
selectivity for JAK family.Multiple pharmacodynamic models evaluating the anti-inflammatory
effect of Flonoltinib Maleate showed that Flonoltinib Maleate showed better therapeutic
effect than the clinical drug Ruxolitinib with lower toxicity.